BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a 15 amino acid sequence derived from a fragment of human gastric juice protein. Since its isolation and characterization in the 1990s, it has become one of the most extensively studied repair-related peptides in preclinical research, accumulating a substantial body of literature across models of musculoskeletal, gastrointestinal, neurological, and vascular injury.
This guide covers what BPC-157 is, how it appears to work based on current mechanistic research, what the published studies show, and the practical handling considerations any researcher working with this compound should know.
What Is BPC-157?
BPC-157 has the amino acid sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its CAS number is 137525-51-0 and molecular weight is 1419.53 g/mol. It is water-soluble, chemically stable in lyophilized form, and has an unusually broad apparent activity profile in animal models — which is both what makes it scientifically interesting and what warrants careful, rigorous study design.
Unlike many peptides derived from circulating hormones or known signaling sequences, BPC-157 was originally isolated from gastric juice in the context of mucosal protection research. The endogenous protein it derives from plays a role in stomach lining defense — which may explain some of its documented effects on gut tissue in research models.
Proposed Mechanisms of Action
BPC-157 does not bind a single, well-characterized receptor the way classical ligands do. Research has implicated several overlapping mechanisms, and the relative contribution of each likely varies by tissue type and model system.
Nitric Oxide System Modulation
One of the most consistently reproduced findings across BPC-157 studies is its interaction with the nitric oxide (NO) system. BPC-157 appears to upregulate endothelial nitric oxide synthase (eNOS) expression and modulate NO bioavailability in vascular tissue. Since NO is a critical mediator of vasodilation, angiogenesis, and inflammatory resolution, this mechanism offers a plausible explanation for BPC-157's reported effects on tissue perfusion and repair.
Crucially, research suggests BPC-157 acts as a modulator rather than a simple agonist — studies using NOS inhibitors can partially block BPC-157's effects, but the peptide also appears to work through NO-independent pathways. This makes mechanistic interpretation more complex, and underscores why in vitro work precedes and informs any in vivo study design.
Growth Factor Receptor Interactions
Several studies have documented BPC-157 interactions with the EGF receptor (EGFR) signaling pathway and vascular endothelial growth factor (VEGF) expression. EGFR activation drives epithelial proliferation and migration — responses relevant to mucosal and wound healing models. VEGF upregulation promotes angiogenesis, the formation of new blood vessels that supply healing tissue.
Research by Sikiric et al. has shown that BPC-157 can upregulate VEGF mRNA expression in ischemic muscle tissue in rat models, with corresponding increases in vessel density at histological examination. Whether this translates to a direct receptor binding event or an indirect downstream effect remains an area of active investigation.
FAK and Cytoskeletal Signaling
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that coordinates cell migration, proliferation, and survival signaling downstream of integrin activation. Multiple studies have shown BPC-157 activates FAK in fibroblasts and other cell types, which promotes cell spreading and migration — responses central to the proliferative phase of wound healing. This may be one of the more direct mechanistic pathways identified so far.
Key Research Findings by System
Musculoskeletal
BPC-157 has been studied in models of tendon, ligament, muscle, and bone repair. A frequently cited series of experiments from the University of Zagreb demonstrated accelerated healing in rat Achilles tendon transection models, with histological evidence of earlier collagen fiber organization and improved tensile properties at biomechanical testing compared to vehicle controls. Similar effects have been reported in rotator cuff, patellar tendon, and transected quadriceps models.
Muscle injury models — including crush injury and segmental defect — have shown BPC-157 accelerates myoblast differentiation and reduces fibrotic scarring in treated animals. Bone repair studies in calvaria defect and fracture models have shown increased osteoblast activity markers and earlier radiographic evidence of bridging compared to controls.
Gastrointestinal
Given its origin in gastric juice research, the GI literature on BPC-157 is extensive. Studies have modeled its effects in NSAID-induced gastric ulcers, inflammatory bowel disease analogs, intestinal anastomosis healing, and short bowel syndrome models. In these systems, BPC-157 consistently reduces lesion size, accelerates mucosal re-epithelialization, and normalizes inflammatory markers.
A particularly interesting finding is that BPC-157 appears effective across both parenteral and oral routes in GI models — an unusual property for a peptide, which would normally be expected to degrade in gastric acid. Proposed explanations include local mucosal effects before absorption, and potential resistance to proteolytic breakdown due to the peptide's sequence composition.
Neurological
BPC-157 research has expanded into neurological models including spinal cord injury, peripheral nerve transection, traumatic brain injury, and dopaminergic system modulation. In nerve transection models, treated animals showed faster functional recovery and improved histological outcomes compared to controls. In brain injury models, BPC-157 reduced lesion volume and improved behavioral outcomes in maze testing.
The compound's apparent interaction with dopamine and serotonin systems has generated interest in psychiatric models as well — some studies report normalization of dopamine receptor sensitivity following dopamine depletion, though the mechanism is not clearly established.
The majority of BPC-157 research is preclinical (animal models). Human clinical trial data is limited. Researchers should design experiments accordingly and not extrapolate animal findings to human outcomes without appropriate evidence.
Forms: BPC-157 Acetate vs. BPC-157 Arginate
BPC-157 is available in two salt forms that appear in research catalogs: acetate salt and arginate salt (also called BPC-157 Stable Salt or BPC-157 SS). The arginate form was developed to address concerns about stability — the acetate form is somewhat hygroscopic and may degrade faster under suboptimal storage conditions.
The arginate salt form replaces the counterion with arginine, reportedly improving aqueous stability and resistance to degradation at physiological pH. For research purposes, both forms are used in the published literature. If your study design involves oral administration or physiological pH conditions, the arginate form may offer advantages. For parenteral administration in controlled conditions, the acetate form is well-characterized.
Reconstitution Protocol
BPC-157 is water-soluble at physiologically relevant concentrations, which makes reconstitution straightforward compared to many other research peptides.
- Allow the vial to reach room temperature before opening — prevents condensation moisture entry
- Add sterile water or bacteriostatic water using a sterile syringe directed at the vial wall, not onto the powder directly
- Gently swirl or invert to dissolve — do not vortex or shake vigorously
- Common working concentrations in research protocols range from 250 mcg/mL to 500 mcg/mL; prepare at the concentration appropriate for your dosing volume
- Bacteriostatic water extends refrigerated shelf life to approximately 3-4 weeks; sterile water solutions should be used within 5-7 days or aliquoted and frozen
- Store reconstituted solution at 4°C or aliquot into single-use volumes and store at −20°C
Storage Requirements
Lyophilized BPC-157 acetate is stable at −20°C for 24 months when stored in sealed, desiccated conditions away from light. Short-term storage at 4°C (refrigerator) is acceptable for up to 3 months for most applications. Room temperature storage degrades the compound over weeks to months — avoid it.
- Long-term (>3 months): −20°C in sealed vial, away from light
- Short-term working stock: 4°C, sealed, use within 3 months
- Reconstituted solution at 4°C: use within 3–4 weeks (bacteriostatic water) or 5–7 days (sterile water)
- Avoid freeze-thaw cycles with reconstituted solutions — aliquot first
- Peptide is sensitive to oxidation; minimize headspace exposure once vial is opened
Research Design Considerations
BPC-157's broad apparent activity profile makes research design especially important. A few considerations for building rigorous protocols:
- Use randomized, blinded study designs where feasible — the published BPC-157 literature has been criticized for lack of blinding in some studies
- Include appropriate vehicle controls (the solvent used to reconstitute BPC-157 should be administered to control groups)
- Document compound source and lot number in methods sections for reproducibility
- Consider dose-response studies before commitment to a single dose — the published literature spans a wide range from 1 ng/kg to 10 mg/kg depending on model and endpoint
- Confirm compound integrity at the study level: HPLC purity should be verified for the specific lot used, and storage conditions should be documented
Nexphoria's BPC-157 is supplied as ≥99% purity by HPLC with identity confirmation by mass spectrometry. Each lot ships with a third-party COA. CAS 137525-51-0.
Regulatory Note
BPC-157 is sold as a research chemical for laboratory use only. It is not FDA-approved, not a dietary supplement, and not approved for human or veterinary use. Researchers are responsible for compliance with all applicable regulations in their jurisdiction. This guide is provided for scientific informational purposes only.